Winton Group’s Abeona Therapeutics ABEO Stock Holding History

Winton Group’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-8,209	Closed	-$671K	–	1376
2019 Q4	$671K	Buy	+8,209	New	+$579K	0.01%	1160

Other funds holding ABEO

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Winton Group's ABEO Position: Q1 2020 in Review

Winton Group sold out of Abeona Therapeutics (ABEO) in Q1 2020, closing a stake of 8,209 shares — an estimated $671K sold.

Winton Group first reported a position in ABEO in Q4 2019 and held it in 1 quarter. The position peaked at $671K in Q4 2019. 80 funds tracked by Wall St. Rank hold ABEO as of Q1 2020.

Winton Group reported no remaining Abeona Therapeutics position as of Q1 2020 after selling out during the quarter.
Winton Group sold 8,209 Abeona Therapeutics shares in Q1 2020, an estimated $671K.
Winton Group first reported a position in Abeona Therapeutics in Q4 2019 and held it in 1 quarter.
Winton Group's Abeona Therapeutics position peaked at $671K in Q4 2019.
80 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2020.

Based on Winton Group's 13F filing for Q1 2020, filed 11 May 2020.